{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:47:07Z","timestamp":1791564427955,"version":"4.3.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.intimp.2021.108503","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T01:33:29Z","timestamp":1641346409000},"page":"108503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation"],"prefix":"10.1016","volume":"104","author":[{"given":"Reem M.","family":"Hazem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Z.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser M.","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2021.108503_b0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes: HEPATOLOGY, Vol. XX, No. X 2016","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.intimp.2021.108503_b0010","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","article-title":"Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: A multicenter large retrospective study","volume":"47","author":"Eguchi","year":"2012","journal-title":"J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.intimp.2021.108503_b0015","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.intimp.2021.108503_b0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40842-020-00097-1","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes: Where do Diabetologists stand?","volume":"6","author":"Tomah","year":"2020","journal-title":"Clinical Diabetes Endocrinology"},{"issue":"4","key":"10.1016\/j.intimp.2021.108503_b0025","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/jdi.12644","article-title":"Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus","volume":"8","author":"Kashiwagi","year":"2017","journal-title":"J. Diabetes Investigation"},{"issue":"7","key":"10.1016\/j.intimp.2021.108503_b0030","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2021.108503_b0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metabolism"},{"issue":"1","key":"10.1016\/j.intimp.2021.108503_b0040","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hepr.13236","article-title":"Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial): Luseogliflozin in T2DM with NAFLD","volume":"49","author":"Sumida","year":"2019","journal-title":"Hepatology Research"},{"issue":"3","key":"10.1016\/j.intimp.2021.108503_b0045","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1210\/en.2015-1588","article-title":"Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice","volume":"157","author":"Obata","year":"2016","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.intimp.2021.108503_b0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.vph.2005.11.011","article-title":"Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: Relation to dysregulated phosphatidylcholine metabolism","volume":"45","author":"Pan","year":"2006","journal-title":"Vasc.Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2021.108503_b0055","first-page":"138","article-title":"Dosage of streptozocin in inducing rat model of type 2 diabetes mellitus","volume":"39","author":"Xiang","year":"2010","journal-title":"J. Hygiene Research"},{"issue":"18","key":"10.1016\/j.intimp.2021.108503_b0060","doi-asserted-by":"crossref","first-page":"429","DOI":"10.21037\/atm.2019.09.03","article-title":"The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus","volume":"7","author":"Leng","year":"2019","journal-title":"Annals of Translational Medicine"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2021.108503_b0065","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"issue":"6","key":"10.1016\/j.intimp.2021.108503_b0070","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.intimp.2021.108503_b0075","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.21874","article-title":"Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet","volume":"46","author":"Matsuzawa","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.intimp.2021.108503_b0080","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.gastro.2006.10.014","article-title":"Insulin Resistance Accelerates a Dietary Rat Model of Nonalcoholic Steatohepatitis","volume":"132","author":"Ota","year":"2007","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.intimp.2021.108503_b0085","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease: Hepatology","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.intimp.2021.108503_b0090","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2337\/dc11-1849","article-title":"Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)","volume":"35","author":"Ortiz-Lopez","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.intimp.2021.108503_b0095","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S1665-2681(19)31825-3","article-title":"Nonalcoholic fatty liver disease and its association with cardiovascular disease","volume":"8","author":"Lizardi-Cervera","year":"2009","journal-title":"Ann. Hepatol."},{"issue":"1\u20133","key":"10.1016\/j.intimp.2021.108503_b0100","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"16","key":"10.1016\/j.intimp.2021.108503_b0105","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic Fatty Liver Disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2021.108503_b0110","first-page":"101","article-title":"Fatty liver disease in diabetes mellitus","volume":"4","author":"Bhatt","year":"2015","journal-title":"Hepatobiliary Surgery and Nutrition"},{"issue":"05","key":"10.1016\/j.intimp.2021.108503_b0115","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1142\/S0192415X14500748","article-title":"Salvianolic Acid A Prevents the Pathological Progression of Hepatic Fibrosis in High-Fat Diet-Fed and Streptozotocin-Induced Diabetic Rats","volume":"42","author":"Qiang","year":"2014","journal-title":"Am. J. Chinese Med."},{"issue":"4","key":"10.1016\/j.intimp.2021.108503_b0120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s13679-016-0232-9","article-title":"Dyslipidemia: Obese or Not Obese\u2014That Is Not the Question","volume":"5","author":"Ipsen","year":"2016","journal-title":"Current Obesity Reports"},{"issue":"9","key":"10.1016\/j.intimp.2021.108503_b0125","doi-asserted-by":"crossref","first-page":"771","DOI":"10.5551\/jat.RV17023","article-title":"Pathophysiology of Diabetic Dyslipidemia","volume":"25","author":"Hirano","year":"2018","journal-title":"J. Atherosclerosis and Thrombosis"},{"issue":"2","key":"10.1016\/j.intimp.2021.108503_b0130","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: More than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev."},{"issue":"22","key":"10.1016\/j.intimp.2021.108503_b0135","doi-asserted-by":"crossref","first-page":"12737","DOI":"10.1073\/pnas.96.22.12737","article-title":"Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes","volume":"96","author":"Foretz","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2021.108503_b0140","first-page":"9","article-title":"Non alcoholic fatty liver disease and metabolic syndrome","volume":"13","author":"Paschos","year":"2009","journal-title":"Hippokratia"},{"issue":"9","key":"10.1016\/j.intimp.2021.108503_b0145","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.intimp.2021.108503_b0150","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.intimp.2021.108503_b0155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.560181","article-title":"A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials","volume":"44","author":"Musso","year":"2012","journal-title":"Ann. Med."},{"issue":"3","key":"10.1016\/j.intimp.2021.108503_b0160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/dia.2013.0167","article-title":"Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin","volume":"16","author":"Mudaliar","year":"2014","journal-title":"Diabetes Technol. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2021.108503_b0165","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/EJE-17-0832","article-title":"MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?","volume":"178","author":"Esterline","year":"2018","journal-title":"Eur. J. Endocrinol."},{"issue":"21","key":"10.1016\/j.intimp.2021.108503_b0170","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.3390\/ijms21217833","article-title":"Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection","volume":"21","author":"Hou","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2021.108503_b0175","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/dom.12923","article-title":"Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity: JOANNIDES et al.","volume":"19","author":"Joannides","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.intimp.2021.108503_b0180","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J. Clin. Endocrinol. Metabolism"},{"issue":"sep19 15","key":"10.1016\/j.intimp.2021.108503_b0185","doi-asserted-by":"crossref","first-page":"g4596","DOI":"10.1136\/bmj.g4596","article-title":"Non-alcoholic fatty liver disease","volume":"349","author":"Sattar","year":"2014","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.intimp.2021.108503_b0190","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: Results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.intimp.2021.108503_b0195","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fendo.2020.00190","article-title":"Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.intimp.2021.108503_b0200","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/medicina55020026","article-title":"Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease","volume":"55","author":"Ore","year":"2019","journal-title":"Medicina"},{"key":"10.1016\/j.intimp.2021.108503_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/7019573","article-title":"Treatment of NASH with Antioxidant Therapy: Beneficial Effect of Red Cabbage on Type 2 Diabetic Rats","volume":"2018","author":"Dal","year":"2018","journal-title":"Oxid. Med. Cell. Longevity"},{"issue":"8","key":"10.1016\/j.intimp.2021.108503_b0210","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/cells8080845","article-title":"Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)","volume":"8","author":"Drescher","year":"2019","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.intimp.2021.108503_b0215","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/1389450116666150427155342","article-title":"Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease","volume":"16","author":"Liu","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.intimp.2021.108503_b0220","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2018.6835","article-title":"Significance of malondialdehyde, superoxide dismutase and endotoxin levels in Budd-Chiari syndrome in patients and a rat model","author":"Cheng","year":"2018","journal-title":"Experimental Therapeutic Med."},{"issue":"6","key":"10.1016\/j.intimp.2021.108503_b0225","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1139\/cjpp-2018-0466","article-title":"A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn 2+ -transporters in cardiomyocytes from insulin-resistant metabolic syndrome rats through inhibition of oxidative stress","volume":"97","author":"Olgar","year":"2019","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108503_b0230","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in vivo myocardial ischemia\u2013reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J. Translational Medicine"},{"issue":"3","key":"10.1016\/j.intimp.2021.108503_b0235","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3803\/EnM.2018.33.3.387","article-title":"Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease","volume":"33","author":"Choi","year":"2018","journal-title":"Endocrinology Metabolism"},{"issue":"5","key":"10.1016\/j.intimp.2021.108503_b0240","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1074-7613(03)00301-7","article-title":"IKK\u03b2 Is Required for Prevention of Apoptosis Mediated by Cell-Bound but Not by Circulating TNF\u03b1","volume":"19","author":"Maeda","year":"2003","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2021.108503_b0245","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.21802","article-title":"Nuclear factor-\u03baB and the hepatic inflammation-fibrosis-cancer axis","volume":"46","author":"Elsharkawy","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.intimp.2021.108503_b0250","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2010.12.008","article-title":"NF-\u03baB, Inflammation, and Metabolic Disease","volume":"13","author":"Baker","year":"2011","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.intimp.2021.108503_b0255","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/hep.20304","article-title":"Diverse regulation of NF-?B and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liver","volume":"40","author":"Romics","year":"2004","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.intimp.2021.108503_b0260","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/j.1572-0241.2004.40009.x","article-title":"Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-\u03baB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis Patients","volume":"99","author":"Ribeiro","year":"2004","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.intimp.2021.108503_b0265","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1053\/j.gastro.2005.09.004","article-title":"NF-\u03baB Activation, Rather Than TNF, Mediates Hepatic Inflammation in a Murine Dietary Model of Steatohepatitis","volume":"129","author":"dela Pe\u00f1a","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2021.108503_b0270","first-page":"1","article-title":"The Role of IL-1 Family Members and Kupffer Cells in Liver Regeneration","volume":"2016","author":"Tan","year":"2016","journal-title":"Biomed Res. Int."},{"issue":"4","key":"10.1016\/j.intimp.2021.108503_b0275","doi-asserted-by":"crossref","first-page":"G663","DOI":"10.1152\/ajpgi.00070.2007","article-title":"Hepatic leukocyte recruitment in response to time-limited expression of TNF-\u03b1 and IL-1\u03b2","volume":"293","author":"Patrick","year":"2007","journal-title":"Am. J. Physiol.-Gastrointestinal LiverPhysiol."},{"issue":"5","key":"10.1016\/j.intimp.2021.108503_b0280","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1053\/j.gastro.2012.09.008","article-title":"Sterile Inflammation in the Liver","volume":"143","author":"Kubes","year":"2012","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.intimp.2021.108503_b0285","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3\/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"11","key":"10.1016\/j.intimp.2021.108503_b0290","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1161\/CIRCRESAHA.117.309633","article-title":"AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System","volume":"120","author":"Salt","year":"2017","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.intimp.2021.108503_b0295","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.bbrc.2004.09.177","article-title":"AMPK inhibits fatty acid-induced increases in NF-\u03baB transactivation in cultured human umbilical vein endothelial cells","volume":"324","author":"Cacicedo","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2021.108503_b0300","doi-asserted-by":"crossref","first-page":"e20848","DOI":"10.1371\/journal.pone.0020848","article-title":"Nitric Oxide-Induced Activation of the AMP-Activated Protein Kinase \u03b12 Subunit Attenuates I\u03baB Kinase Activity and Inflammatory Responses in Endothelial Cells","volume":"6","author":"Bess","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2021.108503_b0305","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.mce.2016.11.010","article-title":"Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation","volume":"440","author":"Mancini","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"issue":"12","key":"10.1016\/j.intimp.2021.108503_b0310","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/febs.13665","article-title":"TGF-\u03b2 signalling and liver disease","volume":"283","author":"Fabregat","year":"2016","journal-title":"The FEBS J."},{"issue":"10","key":"10.1016\/j.intimp.2021.108503_b0315","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/dom.12307","article-title":"Efficacy and safety of empagliflozin for type 2 diabetes: A systematic review and meta-analysis","volume":"16","author":"Liakos","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.intimp.2021.108503_b0320","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.intimp.2021.108503_b0325","article-title":"Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet","volume":"265","author":"Vickers","year":"2014","journal-title":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"},{"key":"10.1016\/j.intimp.2021.108503_b0330","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biopha.2018.03.176","article-title":"Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy","volume":"103","author":"Abdel-Wahab","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.intimp.2021.108503_b0335","doi-asserted-by":"crossref","first-page":"e112394","DOI":"10.1371\/journal.pone.0112394","article-title":"The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2021.108503_b0340","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetology Metabolic Syndrome"},{"issue":"3","key":"10.1016\/j.intimp.2021.108503_b0345","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2559.2005.02226.x","article-title":"The value of alpha-SMA in the evaluation of hepatic fibrosis severity in hepatitis B infection and cirrhosis development: A histopathological and immunohistochemical study","volume":"47","author":"Akpolat","year":"2005","journal-title":"Histopathology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921011395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921011395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:32:20Z","timestamp":1761586340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921011395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":69,"alternative-id":["S1567576921011395"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108503","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108503"}}